Ten years have passed since stem cell treatments appeared in Korea, but they have yet to produce commercial results. Medipost's CARTISTEM is recording annual sales of 10 billion won in Korea, but there is virtually no overseas sales.

According to the Financial Supervisory Service on the 2nd, Medipost's sales of stem cell treatments in the first quarter were 4.5 billion won, up 3.5% from a year earlier. Medipost's stem cell therapy is the only treatment for osteoarthritis, CARTISTEM. CARTISTEM is a drug mainly composed of stem cells derived from cord blood of the same kind. Medipost succeeded in developing the world's first cord blood-derived stem cell therapy using cord blood stem cells from others, and